Published in J Urol on October 01, 1993
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
Antibacterial nature of prostatic fluid. Nature (1968) 3.68
Relative mutation rates at di-, tri-, and tetranucleotide microsatellite loci. Proc Natl Acad Sci U S A (1997) 3.32
Error detection for genetic data, using likelihood methods. Am J Hum Genet (1996) 3.11
Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol (1978) 2.74
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer (1989) 2.57
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology (1979) 2.13
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest (1992) 2.09
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med (1974) 2.05
New explicit expressions for relative frequencies of single-nucleotide polymorphisms with application to statistical inference on population growth. Genetics (2003) 1.97
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
Adult urological sarcoma. J Urol (1992) 1.94
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol (1997) 1.93
Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol (1998) 1.88
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Development and progression of clubbing and scarring in children with recurrent urinary tract infections. Radiology (1974) 1.78
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
A power analysis of microsatellite-based statistics for inferring past population growth. Mol Biol Evol (2000) 1.69
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res (1991) 1.59
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol (1998) 1.53
Prostate cancer: emerging concepts. Part I. Ann Intern Med (1996) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
Juvenile papillomatosis of the breast. A follow-up study of 41 patients having biopsies before 1979. Am J Clin Pathol (1990) 1.48
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol (1996) 1.45
Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer (1988) 1.44
Application of a time-dependent coalescence process for inferring the history of population size changes from DNA sequence data. Proc Natl Acad Sci U S A (1998) 1.44
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Endoscopic diagnosis of advanced gastric cancer. Factors influencing yield. Gastroenterology (1975) 1.40
Malignant lymphoma of the breast. A study of 53 patients. Ann Surg (1987) 1.38
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
Prostatic antibacterial factor. Identity and significance. Urology (1976) 1.30
Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol (1976) 1.27
A note on distributions of times to coalescence, under time-dependent population size. Theor Popul Biol (2003) 1.24
Screening for lung cancer. The Mayo Lung Project revisited. Cancer (1993) 1.24
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
beta-Glucosidase in Candida albicans and its application in yeast identification. J Clin Microbiol (1987) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Urinary tract infections in children. Part I-- Young girls with non-refluxing ureters. West J Med (1974) 1.18
Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ (1996) 1.17
The natural history of lung cancer in a periodically screened population. Biometrics (1987) 1.15
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol (1997) 1.14
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (1993) 1.13
Bacteriologic and hormonal observations of the urethra and vaginal vestibule in normal, premenopausal women. J Urol (1970) 1.12
Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin Chem (1992) 1.12
Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry (1993) 1.11
Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer (1990) 1.11
Rate and directionality of mutations and effects of allele size constraints at anonymous, gene-associated, and disease-causing trinucleotide loci. Mol Biol Evol (1999) 1.10
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer (1987) 1.10
Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol (1994) 1.10
Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol (1992) 1.09
Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet (1987) 1.09
Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta (1998) 1.09
Three-day treatment of urinary tract infections. J Urol (1980) 1.08
Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol (1996) 1.08
Xanthogranulomatous pyelonephritis masquerading as occult malignancy. Urology (1978) 1.08
Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol (1997) 1.08
Allelic deletions in renal tumors: histopathological correlations. Cancer Res (1993) 1.07
Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract (2009) 1.06
Spectrum-analysis and neural networks for imaging to detect and treat prostate cancer. Ultrason Imaging (2001) 1.06
The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol (1978) 1.05
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol (2000) 1.05
Management of children with urinary tract infections: the Stanford experience. Urology (1975) 1.03
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol (1987) 1.03
Site specific predictors of positive margins at radical prostatectomy: an argument for risk based modification of technique. J Urol (1998) 1.03
Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology (1997) 1.03
Are excretory urograms necessary in evaluating women with urinary tract infection? J Urol (1979) 1.01
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol (1994) 1.01
Combating prostate cancer. Sci Am (1998) 1.00
The "ferruginous body" content of lung tissue: a quantitative study of eighty-six patients. Acta Cytol (1972) 1.00
Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol (1989) 1.00
Cellular changes and induction of apoptosis in human promyelocytic HL-60 cells infected with the agent of human granulocytic ehrlichiosis (HGE). Biochem Biophys Res Commun (1997) 0.99
Modeling of long-term screening for lung carcinoma. Cancer (2001) 0.99
Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol (1990) 0.99
Radical cystectomy in the octogenarian. J Urol (1997) 0.98
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol (1982) 0.97
Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol (1994) 0.97
A re-appraisal of treatment in chronic bacterial prostatitis. J Urol (1979) 0.96
Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol Endocrinol (1997) 0.96
Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis, and adenocarcinoma. Invest Urol (1976) 0.96
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol (1995) 0.95
DNA dinucleotide evolution in humans: fitting theory to facts. Genetics (2001) 0.95
Controlled transport and focusing of laser-accelerated protons with miniature magnetic devices. Phys Rev Lett (2008) 0.94